Udik Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 24-12-2024
- Paid Up Capital ₹ 0.12 M
as on 24-12-2024
- Company Age 26 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.00 M
as on 24-12-2024
- Revenue 10.18%
(FY 2020)
- Profit 12.69%
(FY 2020)
- Ebitda -2.88%
(FY 2020)
- Net Worth 16.38%
(FY 2020)
- Total Assets -2.05%
(FY 2020)
About Udik Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.12 M.
The company currently has active open charges totaling ₹1.00 M.
Rakesh Gupta, Asha Gupta, and Sarthak Gupta serve as directors at the Company.
- CIN/LLPIN
U24232UP1998PTC023882
- Company No.
023882
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
25 Sep 1998
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Bareilly, Uttar Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Udik Pharmaceuticals Private Limited offer?
Udik Pharmaceuticals Private Limited offers a wide range of products and services, including Vitamins & Supplements, Mineral Supplements.
Who are the key members and board of directors at Udik Pharmaceuticals?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rakesh Gupta  | Director | 25-Sep-1998 | Current |
| Asha Gupta | Director | 15-Dec-2002 | Current |
| Sarthak Gupta | Additional Director | 05-Dec-2023 | Current |
Financial Performance of Udik Pharmaceuticals.
Udik Pharmaceuticals Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 10.18% increase. The company also saw a substantial improvement in profitability, with a 12.69% increase in profit. The company's net worth Soared by an impressive increase of 16.38%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Udik Pharmaceuticals?
In 2020, Udik Pharmaceuticals had a promoter holding of 58.33% and a public holding of 41.67%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
₹1.00 M
₹0
Charges Breakdown by Lending Institutions
- The Nainital Bank Limited : 0.10 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 01 Sep 2006 | The Nainital Bank Limited | ₹1.00 M | Open |
How Many Employees Work at Udik Pharmaceuticals?
Udik Pharmaceuticals has a workforce of 21 employees as of Mar 28, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Udik Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Udik Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
